VAERS Explorer
Back to explore

Report #2900394

Received Jun 17, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
1 yrs
State
PA
Recovered
Unknown
Vaccinated
Nov 4, 2025
Onset
Apr 21, 2026
Days to onset
168
Hospital days

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
HEPAHEP A (VAQTA)MERCK & CO. INC.1Y013274
HEPAHEP A (VAQTA)MERCK & CO. INC.2Z012745

Symptoms (2)

Inappropriate schedule of product administrationNo adverse event

Symptom narrative

No additional AE reported.; a patient received their second dose of VAQTA too early.; This Spontaneous report was received from Nurse and referred to a/an 1-year-old ( Race Unknown ) ( Ethnicity Unknown) Infant patient of unknown gender. The patient's medical history was not reported. The patient's past medications were not reported. The patient's concomitant medications were not reported. On 04-Nov-2025, the patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 (0.50 mL) (total) (Batch/Lot Number: Y013274) (Expiration date: 26-Dec-2025) (Dose Text: 0.5ML). On 21-Apr-2026, the patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 (0.50 mL) (total) (Batch/Lot Number: Z012745) (Expiration date: 16-Oct-2026) (Dose Text: 0.5ML). The patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 for the treatment of prophylaxis, The patient started therapy with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 for the treatment of prophylaxis, On 21-Apr-2026, the patient experienced a patient received their second dose of VAQTA too early. (Inappropriate schedule of product administration). On an unknown date, the patient experienced No additional AE reported. (No adverse event). The Outcome of Inappropriate schedule of product administration was not provided. The Outcome of No adverse event was not provided. The action taken with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding Inappropriate schedule of product administration was Not applicable with Not Applicable dechallenge and rechallenge results. The action taken with Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding Inappropriate schedule of product administration was Not applicable with Not Applicable dechallenge and rechallenge results. Case Assessments: Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding No adverse event with Not Applicable dechallenge and rechallenge results. Case Assessments: Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 regarding No adverse event with Not Applicable dechallenge and rechallenge results. The Nurse considered the event No adverse event (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095, the event Inappropriate schedule of product administration (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095, the event Inappropriate schedule of product administration (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095, and the event No adverse event (,) to be not assessed to Hepatitis A Vaccine, Inactivated, Pediatric, 25 u/0.5mL Suspension for injection 64457227:4095 The Nurse considered the event No adverse event to be non-serious and the event Inappropriate schedule of product administration to be non-serious